Velzomy 3.5 Mg Powder For Solution For Injection 3.5 mg Powder for solution for injection.
PDF Leaflet Revision Date: 20 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and mantle cell lymphoma.
Dosage (summary)
Starting dose: 1.3 mg/mu00b2 twice weekly for 2 weeks, followed by a 10-day rest.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding should be discontinued during treatment.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Oral hypoglycemics
Contraindications
- Hypersensitivity to bortezomib
- Acute diffuse infiltrative pulmonary disease
Common side effects
- Nausea
- Diarrhoea
- Constipation
- Fatigue
- Thrombocytopenia
- Peripheral neuropathy
Counselling Points
- Use effective contraception during treatment
- Monitor for signs of neuropathy
- Avoid driving if experiencing dizziness or hypotension
Serious warnings
- Fatal intrathecal administration
- Gastrointestinal toxicity
- Cardiac failure
- PML risk
Important Disclaimer
The Velzomy 3.5 Mg Powder For Solution For Injection 3.5 mg Powder for solution for injection. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
